Fig. 2.
Antitumor activity of trebananib. a Time to disease progression. Tumor type: 1 Colon, 2 Bladder, 3 Stomach (gastrointestinal stromal tumor), 4 Pancreas. b The maximum percent change in target lesions. SLD sum of the longest diameter. Tumor type: 1 Colon, 2 Bladder, 3 Stomach (gastrointestinal stromal tumor). One patient with colon cancer in the 3-mg/kg cohort and one with bladder cancer in the 30-mg/kg cohort had a best response of partial response